These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 3493209

  • 1. Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.
    Hinuma S, Naruo K, Ootsu K, Houkan T, Shiho O, Tsukamoto K.
    Immunology; 1987 Feb; 60(2):173-9. PubMed ID: 3493209
    [Abstract] [Full Text] [Related]

  • 2. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
    Hinuma S, Naruo K, Shiho O, Tsukamoto K.
    Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
    [Abstract] [Full Text] [Related]

  • 3. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 4. Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.
    Naruo KI, Hinuma S, Shiho O, Houkan T, Ootsu K, Tsukamoto K.
    Clin Exp Immunol; 1989 May 01; 76(2):278-83. PubMed ID: 2788049
    [Abstract] [Full Text] [Related]

  • 5. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.
    Yoshioka T, Sato S, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1986 Aug 01; 77(8):825-32. PubMed ID: 3093429
    [Abstract] [Full Text] [Related]

  • 6. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice.
    Gorelik E.
    Cancer Res; 1987 Feb 01; 47(3):809-15. PubMed ID: 3802083
    [Abstract] [Full Text] [Related]

  • 7. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.
    Gately MK, Anderson TD, Hayes TJ.
    J Immunol; 1988 Jul 01; 141(1):189-200. PubMed ID: 3259967
    [Abstract] [Full Text] [Related]

  • 8. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R, Kitagawa T, Koizumi K, Sato K, Homma M.
    J Biol Response Mod; 1989 Dec 01; 8(6):676-90. PubMed ID: 2600605
    [Abstract] [Full Text] [Related]

  • 9. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ, Yang J, Shu S, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3899-909. PubMed ID: 2871106
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Asialo-GM1-positive T killer cells are generated in F1 mice injected with parental spleen cells.
    Knobloch C, Dennert G.
    J Immunol; 1988 Feb 01; 140(3):744-9. PubMed ID: 2448375
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion.
    Anderson TD, Hayes TJ, Gately MK, Bontempo JM, Stern LL, Truitt GA.
    Lab Invest; 1988 Nov 01; 59(5):598-612. PubMed ID: 3263543
    [Abstract] [Full Text] [Related]

  • 14. Treatment of mice with anti-asialo-GM1 antibody or poly-I:C: effects on metastasis dissociable from modulation of macrophage antitumor activity.
    Riser BL, Laybourn KA, Varani J.
    Nat Immun Cell Growth Regul; 1988 Nov 01; 7(5-6):305-15. PubMed ID: 3221908
    [Abstract] [Full Text] [Related]

  • 15. The suppressive effect of anti-asialo GM1 antibody on low-dose streptozotocin-induced diabetes in CD-1 mice.
    Maruyama T, Watanabe K, Yanagawa T, Kasatani T, Kasuga A, Shimada A, Takei I, Suzuki Y, Kataoka K, Saruta T.
    Diabetes Res; 1991 Apr 01; 16(4):171-5. PubMed ID: 1802483
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Purification and target cell range of in vivo elicited blast natural killer cells.
    Biron CA, Pedersen KF, Welsh RM.
    J Immunol; 1986 Jul 15; 137(2):463-71. PubMed ID: 3722814
    [Abstract] [Full Text] [Related]

  • 19. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
    Butler LD, Browne CP, Layman NK, Riedl P, Tang J, Marder P, DeLong D, Manetta J, Bobbitt L, Strnad J.
    Cancer Res; 1988 Nov 01; 48(21):6081-9. PubMed ID: 3048654
    [Abstract] [Full Text] [Related]

  • 20. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL, Herberman RB, Olszowy MW, Cramer DV, Salup RR, Reynolds CW, Hiserodt JC.
    Cancer Res; 1988 Feb 15; 48(4):884-90. PubMed ID: 3257412
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.